2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
318
Squamous Cell Carcinoma of Head and Neck
169
Head and Neck Neoplasms
151
Carcinoma, Non-Small-Cell Lung
97
Colonic Neoplasms
90
Rectal Neoplasms
82
Neoplasm Metastasis
72
Neoplasms
60
Pancreatic Neoplasms
40
Carcinoma, Squamous Cell
40
Lung Neoplasms
35
Esophageal Neoplasms
25
Breast Neoplasms
22
Stomach Neoplasms
20
Recurrence
20
Carcinoma
18
Laryngeal Neoplasms
17
Tongue Neoplasms
16
Mouth Neoplasms
16
Oropharyngeal Neoplasms
14
Esophageal Squamous Cell Carcinoma
14
Salivary Gland Neoplasms
12
Adenocarcinoma Of Esophagus
12
Hypopharyngeal Neoplasms
11
Colorectal Cancer Metastatic
11
Laryngeal Diseases
10
Adenocarcinoma of Lung
10
Uterine Cervical Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Ovarian Neoplasms
9
Interventions
osimertinib
2
sotorasib
1
pembrolizumab
1
nazartinib
1
cobimetinib
1
Waiting Lists
1
Lovastatin
1
Lamotrigine
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Noonan Syndrome
×
Cetuximab
×
Clear all
NCT04670679
2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1
Active not recruiting
90 enrolled